Re-appointment of Internal Auditors and Cost Auditor for the FY 2026-27
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sandu Pharmaceuticals reported standalone audited results for FY 2025-26 with revenue from operations of Rs 1685.34 lakhs. Profit after tax for the year stood at Rs 17.651 lakhs with EPS of Rs 1.83 per share. The board recommended a final dividend of Rs 1 per equity share (10%) for FY 2025-26, subject to shareholder approval. The company reappointed M/s Shekhar Joshi & Co as Cost Auditor and M/s Akhil Pai & Co and M/S Uday & Uday Associates as Internal Auditors for FY 2026-27. Statutory auditors Dileep & Prithvi issued an unmodified (clean) audit opinion. The company also confirmed it is not classified as a Large Corporate under SEBI norms.
Revenue declined from Rs 1877.46 lakhs in the prior year, indicating top-line pressure. However, a clean audit opinion and a modest dividend signal stability for shareholders. The stock is unlikely to react sharply given routine auditor appointments and no governance red flags.